Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US-8962636-B2 · Feb 24, 2015 · US
DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9155705B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9155705-B2 |
| Application number | US-93563409-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 2, 2009 |
| Priority date | Apr 3, 2008 |
| Publication date | Oct 13, 2015 |
| Grant date | Oct 13, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
First claim
Opening claim text (preview).
The invention claimed is: 1. A solid pharmaceutical composition comprising or made from: (a) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in a dosage range from about 0.5 mg to about 10 mg, (b) metformin hydrochloride, (c) a pharmaceutical excipient, and (d) about 1 mg to 50 mg of L-arginine. 2. The pharmaceutical composition according to claim 1 , wherein the 1-[(4-methyl-quinazolin-2-yl)methy…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9155705B2 cover?
- The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.
- Who is the assignee on this patent?
- Friedl Thomas, Braun Michael, Egusa Kenji, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/522. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).